3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Encore Medical does not have enough data to calculate 3-Year ROIIC %.
Encore Medical (AMEX:EMI) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Encore Medical 3-Year ROIIC % Related Terms
Encore Medical 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Encore Medical's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Encore Medical's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Encore Medical 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Encore Medical's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Encore Medical's 3-Year ROIIC % falls into.
Encore Medical's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -0.829 (Dec. 2025) - (Dec. 2022) )
/
( 2.019 (Dec. 2025) - (Dec. 2022) )
=
/
=
N/A%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Encore Medical (EMI) has a 3-Year ROIIC % of 0.00 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Encore Medical and its competitors.
Is Encore Medical's 3-Year ROIIC % too high?
Encore Medical's current 3-Year ROIIC % is 0.00.
How does Encore Medical's 3-Year ROIIC % compare to ?
Encore Medical's 3-Year ROIIC % of 0.00 can be compared against companies in the Medical Devices & Instruments industry. The industry median 3-Year ROIIC % is 1.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.67, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Encore Medical and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Encore Medical's current 3-Year ROIIC % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Encore Medical stock overvalued right now?
Encore Medical (EMI) has a current 3-Year ROIIC % of 0.00. The current 3-Year ROIIC % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Encore Medical (EMI), the current 3-Year ROIIC % is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Encore Medical Inc develops, manufactures, and markets septal occlusion devices for the repair of certain cardiac defects. Its products have been implanted in approximately 35,000 patients outside the United States. Its closure device is designed to correct a cardiac defect, generally diagnosed in adulthood, known as a patent foramen ovale (PFO). The company also currently market and sell septal occlusion devices for the transcatheter closure of atrial septal defects (ASD).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMI has been successfully added to your